Publications by authors named "G Ingle"

Article Synopsis
  • - The study investigates cardiovascular autonomic dysfunction in individuals with hereditary transthyretin amyloidosis, revealing that 27% reported symptoms at disease onset, increasing to 78% at the first evaluation (T1) after 4.5 years.
  • - A total of 124 individuals participated, with cardiovascular autonomic failure found in 75% of symptomatic patients and 64% of asymptomatic TTR variant carriers, highlighting a significant underestimate of autonomic issues in early stages.
  • - The findings suggest that autonomic dysfunction can be an early indicator of disease progression, with a faster progression rate observed in individuals reporting autonomic symptoms, emphasizing the need for routine autonomic function testing for better diagnosis and monitoring.
View Article and Find Full Text PDF

A 62-year-old man attended ophthalmology for a simple ptosis repair. He had a chronic cough, a Horner's syndrome with post-gustatory hyperhidrosis. He was referred to the respiratory and neurology teams.

View Article and Find Full Text PDF

Background And Purpose: Pure autonomic failure (PAF) is a rare progressive neurodegenerative disease characterized by neurogenic orthostatic hypotension at presentation, without other neurological abnormalities. Some patients may develop other central neurological features indicative of multiple system atrophy or a Lewy body disorder. There are currently no biomarkers to assess possible central nervous system involvement in probable PAF at an early stage.

View Article and Find Full Text PDF

Activation of the glucagon-like peptide-1 (GLP-1) receptor stimulates insulin release, lowers plasma glucose levels, delays gastric emptying, increases satiety, suppresses food intake, and affords weight loss in humans. These beneficial attributes have made peptide-based agonists valuable tools for the treatment of type 2 diabetes mellitus and obesity. However, efficient, and consistent delivery of peptide agents generally requires subcutaneous injection, which can reduce patient utilization.

View Article and Find Full Text PDF

Regardless of recent advances in cancer treatment, ovarian cancer (OC) patients have had a five-year survival rate of 48% in the last few decades. Diagnosis at the advanced stage, disease recurrence, and lack of early biomarkers are the severe clinical challenges associated with disease survival rate. Identifying tumor origin and developing precision drugs will effectively advance OC patient's treatment.

View Article and Find Full Text PDF